Asymmetric Transfer Hydrogenation of Heterocyclic Compounds in Continuous Flow Using an Immobilized Chiral Phosphoric Acid as the Catalyst
Synthesis · 01.08.2023 · 55 (15) · 2361-2369
DOI: 10.1055/a-2085-5256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synthesis, erschienen am 01.08.2023. Verfasst von Pavel Nagorny und 2 weiteren Autor:innen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Science Foundation.
Abstract (Originalsprache)
This manuscript describes transfer hydrogenation of bicyclic nitrogen-containing heterocyclic compounds using the immobilized chiral phosphoric acid catalyst (R)-PS-AdTRIP in batch and continuous flow. A significant improvement in enantioselectivities is achieved in continuous flow with a fluidized bed reactor packed with (R)-PS-AdTRIP when the flow rate is increased from 0.2 mL/min to 2.0–2.5 mL/min. The optimized continuous flow conditions consistently provide 4–6% ee higher selectivity than transfer hydrogenation in batch with 2 mol% of (R)-PS-AdTRIP, and are used to generate multiple chiral products with the same fluidized bed reactor.
Förderung
- National Science Foundation
Zitieren
APA
Nagorny, P., Zhelavskyi, O., & Jhang, Y. (2023). Asymmetric Transfer Hydrogenation of Heterocyclic Compounds in Continuous Flow Using an Immobilized Chiral Phosphoric Acid as the Catalyst. Synthesis, 55(15), 2361-2369. https://doi.org/10.1055/a-2085-5256
Vancouver
Nagorny P, Zhelavskyi O, Jhang Y. Asymmetric Transfer Hydrogenation of Heterocyclic Compounds in Continuous Flow Using an Immobilized Chiral Phosphoric Acid as the Catalyst. Synthesis. 2023;55(15):2361-2369. doi:10.1055/a-2085-5256
BibTeX
@article{Nagorny2023,
author = {Nagorny, Pavel and Zhelavskyi, Oleksii and Jhang, Yin-Jia},
title = {Asymmetric Transfer Hydrogenation of Heterocyclic Compounds in Continuous Flow Using an Immobilized Chiral Phosphoric Acid as the Catalyst},
journal = {Synthesis},
year = {2023},
volume = {55},
number = {15},
pages = {2361--2369},
doi = {10.1055/a-2085-5256}
}
EUVIMED